Clinical Coagulation, Malmö
521 – 530 of 659
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A
- Contribution to journal › Article
-
Mark
The 80th anniversary of von Willebrand's disease: history, management and research
- Contribution to journal › Scientific review
-
Mark
Practice patterns in haemophilia A therapy - global progress towards optimal care
- Contribution to journal › Article
-
Mark
Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics.
- Contribution to journal › Article
-
Mark
Polymorphisms in the IL-10 but not in the IL-1{beta} and IL-4 genes are associated with inhibitor development in patients with hemophilia A.
- Contribution to journal › Article
-
Mark
Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia
- Contribution to journal › Article
-
Mark
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.
- Contribution to journal › Article
-
Mark
Von Willebrand's disease: clinical management
- Contribution to journal › Article
-
Mark
The next generation of hemophilia treatment specialists
- Contribution to journal › Article
-
Mark
Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
- Contribution to journal › Article